OPNOA
Asset Logo

Openn Negotiation Limited

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Openn Negotiation Limited - Option Expiring 15-Jun-2025

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in OPNOA

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in OPNOA

N/A
OPNOA investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in OPNOA also invest in...

Want more shares? Try these...

Opthea Limited

OPT

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

πŸ™Œ Performance (5Yr p.a)

-15.21%

πŸ“Š Share price

$0.80 AUD

🧬 BIOTECHNOLOGY

Find Out More

πŸ“Š Share price

$0.41 AUD

Opyl Ltd. is an information technology company, which engages in the development of digital tools that improve the healthcare experience for patients, deliver deep market insights from social media data, and improve the efficiency and value of clinical research process. The company is headquartered in St Kilda, Victoria. The firm leverages data and technology to transform the landscape of clinical trials and medical research. The company is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The firm is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.

πŸ™Œ Performance (5Yr p.a)

193.33%

πŸ“Š Share price

$0.02 AUD

πŸ€– TECHNOLOGY

Openn Negotiation Ltd. engages in buying and selling of real estate properties. The Openn platform facilitates a negotiation process, featuring streamlined digital contracting and automated communication tools, which enhance a property transaction. The solution provides buyers with real-time feedback through their device on how much competition exists and where their price stands in the negotiation, resulting in an optimal sales outcome. The platform offers a number of sales methods, including traditional offer and acceptance, online auction, and tender. Depending on the sales method chosen by the seller and agent, Openn provides in-app feedback on competition for the property and how their offer price compares in the negotiation, ensuring efficiency, transparency and the opportunity to win the bidding or make the winning offer.

πŸ“Š Share price

$0.01 AUD

πŸ”¨ COMMERCIAL SERVICES & SUPPLIES

Compare
Add to watchlist